These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8389655)

  • 1. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.
    Nieweg OE; Kim EE; Wong WH; Broussard WF; Singletary SE; Hortobagyi GN; Tilbury RS
    Cancer; 1993 Jun; 71(12):3920-5. PubMed ID: 8389655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
    Utech CI; Young CS; Winter PF
    Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
    Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
    Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
    Crowe JP; Adler LP; Shenk RR; Sunshine J
    Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
    Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
    Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan.
    Crippa F; Agresti R; Donne VD; Pascali C; Bogni A; Chiesa C; De Sanctis V; Schiavini M; Decise D; Bombardieri E
    Tumori; 1997; 83(2):542-3. PubMed ID: 9226015
    [No Abstract]   [Full Text] [Related]  

  • 9. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
    Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
    Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in staging of esophageal cancer with the addition of positron emission tomography.
    Block MI; Patterson GA; Sundaresan RS; Bailey MS; Flanagan FL; Dehdashti F; Siegel BA; Cooper JD
    Ann Thorac Surg; 1997 Sep; 64(3):770-6; discussion 776-7. PubMed ID: 9307472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer.
    Danforth DN; Aloj L; Carrasquillo JA; Bacharach SL; Chow C; Zujewski J; Whatley M; Galen B; Merino M; Neumann RD
    Breast Cancer Res Treat; 2002 Sep; 75(2):135-46. PubMed ID: 12243506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes.
    Wahl RL; Kaminski MS; Ethier SP; Hutchins GD
    J Nucl Med; 1990 Nov; 31(11):1831-5. PubMed ID: 2230996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
    Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
    Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Whole body positron emission tomography in breast cancer].
    Nitzsche EU; Hoh CK; Dalbohm NM; Glaspy JA; Phelps ME; Moser EA; Hawkins RA
    Rofo; 1993 Apr; 158(4):293-8. PubMed ID: 8386565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
    Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
    J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.